Mechanistically, our results indicate the molecular events underlying IKKε's involvement in AAA formation depend at least in part on the accelerated phosphorylation of ERK1/2, suggesting that IKKε is a potential novel therapeutic target for AAA progression. The gene discussed is MAPK3; the disease is triple-A syndrome.